Result of Oversubscribed WRAP Retail Offer
ValiRx PLC announced the successful oversubscription of its WRAP Retail Offer, raising approximately £150,000 through the issuance of 75,000,000 new ordinary shares at 0.2 pence each. Combined with a prior placing and subscription of £1,005,000, the total gross proceeds from the fundraising amount to approximately £1,155,000. The company also plans to grant 577,500,000 Fundraising Warrants and 50,000,000 Broker Warrants, subject to shareholder approval. Chief Executive Officer Mark Eccleston participated in the retail offer, purchasing 25,000,000 new ordinary shares for £5,000, increasing his resultant interest to 6.42% of the enlarged issued share capital. Admission of the new shares to AIM is anticipated on or around June 1, 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to confirm, further to the announcement made on 18 May 2026, the result of WRAP Retail Offer. The WRAP Retail Offer was substantially oversubscribed, demonstrating strong support from retail shareholders.
The WRAP Retail Offer has raised gross proceeds of approximately £150,000, through the issue of 75,000,000 new ordinary shares of 0.1 pence each at a price of 0.2 pence per share (the "WRAP Retail Offer Shares"). With the gross proceeds of the Placing and Subscription of £1,005,000, in aggregate, the Company has therefore raised gross proceeds of approximately £1,155,000 at a price of 0.2 pence per New Ordinary Share. In connection with the Fundraising the Company will (subject to the approval of shareholders) grant 577,500,000 Fundraising Warrants and 50,000,000 Broker Warrants.
The grant of the Fundraising Warrants and Broker Warrants are subject to the passing of the Fundraising Resolutions at the General Meeting.
Director / PDMR Shareholding
Further to the announcement released on 15 May 2026, Mark Eccleston, Chief Executive Officer of the Company, indicated his intention to participate in the WRAP Retail Offer. Pursuant to the WRAP Retail Offer, on 20 May 2026, Mr Eccleston purchased 25,000,000 New Ordinary Shares at a price of 0.2 pence per New Ordinary Share. Details of Mr Eccleston's shareholding is set out below.
| Mark Eccleston | 0.2 pence | 25,000,000 | 84,746,187 | 6.42% |
Further details are set out in the Notification of Dealing Form below.
Related Party Transaction
The participation of Mark Eccleston in the WRAP Retail Offer is a "related party transaction" for the purposes of Rule 13 of the AIM Rules (the "Transaction"). Cathy Tralau-Stewart and Martin Gouldstone, being directors of the Company independent of the Transaction, having consulted with the Company's nominated adviser, Cairn Financial Advisers LLP, consider that the terms of the Transaction are fair and reasonable in so far as the Company's shareholders are concerned.
Admission
Application has been made to the London Stock Exchange for the Placing Shares, Subscription Shares and WRAP Retail Offer Shares to be admitted to trading on AIM. It is anticipated that Admission will become effective and that dealings in the Placing Shares, Subscription Shares, WRAP Retail Offer Shares will commence on AIM at 8.00 a.m. on or around 1 June 2026.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 1,320,301,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7:00 a.m. on 15 May 2026.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/r6gp4P |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti / James Western | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Broker) Damon Heath Andrew Gutmann | Tel: +44 (0) 20 7186 9000 |
| Winterflood Retail Access Platform Sophia Bechev / Kaitlan Billings | +44(0) 20 3100 0286 WRAP@winterflood.com |
| V Formation (Public Relations) Jocelyn Braithwaite | +44 (0) 115 646 5491 www.vformation.co.uk Jocelyn@vformation.co.uk |
The Company's LEI is 213800VQKB9SJCQDET40.
| a. | Name | Mark Eccleston |
| 2 | Reason for notification | |
| a. | Position/Status | Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Purchase of shares through the WRAP Retail Offer |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 0.20 pence | 25,000,000 | |
| d. | Aggregated information - Aggregated Volume - Price | See above |
| f. | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.